MHC class II and CD80 tumor cell–based vaccines are potent activators of type 1 CD4⁺ T lymphocytes provided they do not coexpress invariant chain

By Ilkovitch Dan   Ostrand-Rosenberg Suzanne  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 525-532

Springer Publishing Company

Access to resources Recommend Favorite

Quality control of MHC class II associated peptides by HLA-DM/H2-M

By Vogt A.B.   Kropshofer H.  

Seminars in Immunology, Vol. 11, Iss. 6, 1999-12 ,pp. : 391-403

Academic Press

Access to resources Recommend Favorite

Intracellular organelles involved in antigen processing and the binding of peptides to class II MHC molecules

By Harding C.V.  

Seminars in Immunology, Vol. 7, Iss. 6, 1995-12 ,pp. : 355-360

Academic Press

Access to resources Recommend Favorite

T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts

By Demeure C.E.   Wolfers J.   Martin-Garcia N.   Gaulard P.   Triebel F.  

European Journal of Cancer, Vol. 37, Iss. 13, 2001-09 ,pp. : 1709-1718

Elsevier

Access to resources Recommend Favorite

Defining MHC class II T helper epitopes for WT1 tumor antigen

By Kobayashi Hiroya   Nagato Toshihiro   Aoki Naoko   Sato Keisuke   Kimura Shoji   Tateno Masatoshi   Celis Esteban  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 7, 2006-07 ,pp. : 850-860

Springer Publishing Company

Access to resources Recommend Favorite